We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s Type 2 Diabetes Drug Sees Success in Late-Stage Trial
Eli Lilly’s Type 2 Diabetes Drug Sees Success in Late-Stage Trial
Eli Lilly said its experimental drug, tirzepatide, reduced blood glucose levels and body weight in type 2 diabetics with increased risk of heart disease more effectively than Sanofi’s blockbuster diabetes drug Lantus (insulin glargine) in a head-to-head phase 3 study.